Renal Medullary Carcinoma: The Bronx Experience

A. Ari Hakimi, Phillip T. Koi, Paul M. Milhoua, Netta M. Blitman, Maomi Li, Vladimir Hugec, Janice P. Dutcher, Reza Ghavamian

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Objectives: Renal medullary carcinoma (RMC) is a devastating and extremely rare malignancy primarily afflicting young men with sickle cell trait. We present our clinical experience with 9 cases of RMC during a 10-year period and briefly review the published data. Methods: A retrospective chart review of 9 cases of RMC during a 10-year period at our institutions was performed. The clinical patient characteristics, presentations, treatments, and outcomes were recorded. The radiographic images and pathologic specimens were reviewed. Applicable studies were selected from a Medline search. Results: All 9 patients had sickle cell trait, the male/female ratio was 6:3, and the age range was 13 to 31 years. All the patients presented with flank pain, two thirds had hematuria, and 3 of the 9 patients presented with a palpable mass. Eight of the nine tumors were right sided, ranging from 4 to 12 cm in the greatest diameter. Of the 9 patients, 7 underwent radical nephrectomy. One patient was deemed to have unresectable disease by the operating surgeon, and one was given initial chemotherapy after biopsy of a metastatic lesion. The neoadjuvant therapies varied. Overall survival ranged from 4 to 16 months, with 2 patients still living at the last follow-up visit. Conclusions: Our urban setting likely explains our relatively large experience with this rare and extremely aggressive tumor. An early diagnosis is critical, and a high index of suspicion should be given to any individual with sickle cell trait and new-onset hematuria, especially in the setting of a right-sided mass. Prospective trials are needed for chemotherapy/immunotherapy, because surgical intervention alone is inadequate.

Original languageEnglish (US)
Pages (from-to)878-882
Number of pages5
JournalUrology
Volume70
Issue number5
DOIs
StatePublished - Nov 2007

Fingerprint

Medullary Carcinoma
Kidney
Sickle Cell Trait
Hematuria
Flank Pain
Drug Therapy
Neoplasms
Neoadjuvant Therapy
Nephrectomy
Immunotherapy
Early Diagnosis
Biopsy
Survival

ASJC Scopus subject areas

  • Urology

Cite this

Hakimi, A. A., Koi, P. T., Milhoua, P. M., Blitman, N. M., Li, M., Hugec, V., ... Ghavamian, R. (2007). Renal Medullary Carcinoma: The Bronx Experience. Urology, 70(5), 878-882. https://doi.org/10.1016/j.urology.2007.06.1124

Renal Medullary Carcinoma : The Bronx Experience. / Hakimi, A. Ari; Koi, Phillip T.; Milhoua, Paul M.; Blitman, Netta M.; Li, Maomi; Hugec, Vladimir; Dutcher, Janice P.; Ghavamian, Reza.

In: Urology, Vol. 70, No. 5, 11.2007, p. 878-882.

Research output: Contribution to journalArticle

Hakimi, AA, Koi, PT, Milhoua, PM, Blitman, NM, Li, M, Hugec, V, Dutcher, JP & Ghavamian, R 2007, 'Renal Medullary Carcinoma: The Bronx Experience', Urology, vol. 70, no. 5, pp. 878-882. https://doi.org/10.1016/j.urology.2007.06.1124
Hakimi AA, Koi PT, Milhoua PM, Blitman NM, Li M, Hugec V et al. Renal Medullary Carcinoma: The Bronx Experience. Urology. 2007 Nov;70(5):878-882. https://doi.org/10.1016/j.urology.2007.06.1124
Hakimi, A. Ari ; Koi, Phillip T. ; Milhoua, Paul M. ; Blitman, Netta M. ; Li, Maomi ; Hugec, Vladimir ; Dutcher, Janice P. ; Ghavamian, Reza. / Renal Medullary Carcinoma : The Bronx Experience. In: Urology. 2007 ; Vol. 70, No. 5. pp. 878-882.
@article{5717737c8c044908b8ac93ecdfcf4237,
title = "Renal Medullary Carcinoma: The Bronx Experience",
abstract = "Objectives: Renal medullary carcinoma (RMC) is a devastating and extremely rare malignancy primarily afflicting young men with sickle cell trait. We present our clinical experience with 9 cases of RMC during a 10-year period and briefly review the published data. Methods: A retrospective chart review of 9 cases of RMC during a 10-year period at our institutions was performed. The clinical patient characteristics, presentations, treatments, and outcomes were recorded. The radiographic images and pathologic specimens were reviewed. Applicable studies were selected from a Medline search. Results: All 9 patients had sickle cell trait, the male/female ratio was 6:3, and the age range was 13 to 31 years. All the patients presented with flank pain, two thirds had hematuria, and 3 of the 9 patients presented with a palpable mass. Eight of the nine tumors were right sided, ranging from 4 to 12 cm in the greatest diameter. Of the 9 patients, 7 underwent radical nephrectomy. One patient was deemed to have unresectable disease by the operating surgeon, and one was given initial chemotherapy after biopsy of a metastatic lesion. The neoadjuvant therapies varied. Overall survival ranged from 4 to 16 months, with 2 patients still living at the last follow-up visit. Conclusions: Our urban setting likely explains our relatively large experience with this rare and extremely aggressive tumor. An early diagnosis is critical, and a high index of suspicion should be given to any individual with sickle cell trait and new-onset hematuria, especially in the setting of a right-sided mass. Prospective trials are needed for chemotherapy/immunotherapy, because surgical intervention alone is inadequate.",
author = "Hakimi, {A. Ari} and Koi, {Phillip T.} and Milhoua, {Paul M.} and Blitman, {Netta M.} and Maomi Li and Vladimir Hugec and Dutcher, {Janice P.} and Reza Ghavamian",
year = "2007",
month = "11",
doi = "10.1016/j.urology.2007.06.1124",
language = "English (US)",
volume = "70",
pages = "878--882",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Renal Medullary Carcinoma

T2 - The Bronx Experience

AU - Hakimi, A. Ari

AU - Koi, Phillip T.

AU - Milhoua, Paul M.

AU - Blitman, Netta M.

AU - Li, Maomi

AU - Hugec, Vladimir

AU - Dutcher, Janice P.

AU - Ghavamian, Reza

PY - 2007/11

Y1 - 2007/11

N2 - Objectives: Renal medullary carcinoma (RMC) is a devastating and extremely rare malignancy primarily afflicting young men with sickle cell trait. We present our clinical experience with 9 cases of RMC during a 10-year period and briefly review the published data. Methods: A retrospective chart review of 9 cases of RMC during a 10-year period at our institutions was performed. The clinical patient characteristics, presentations, treatments, and outcomes were recorded. The radiographic images and pathologic specimens were reviewed. Applicable studies were selected from a Medline search. Results: All 9 patients had sickle cell trait, the male/female ratio was 6:3, and the age range was 13 to 31 years. All the patients presented with flank pain, two thirds had hematuria, and 3 of the 9 patients presented with a palpable mass. Eight of the nine tumors were right sided, ranging from 4 to 12 cm in the greatest diameter. Of the 9 patients, 7 underwent radical nephrectomy. One patient was deemed to have unresectable disease by the operating surgeon, and one was given initial chemotherapy after biopsy of a metastatic lesion. The neoadjuvant therapies varied. Overall survival ranged from 4 to 16 months, with 2 patients still living at the last follow-up visit. Conclusions: Our urban setting likely explains our relatively large experience with this rare and extremely aggressive tumor. An early diagnosis is critical, and a high index of suspicion should be given to any individual with sickle cell trait and new-onset hematuria, especially in the setting of a right-sided mass. Prospective trials are needed for chemotherapy/immunotherapy, because surgical intervention alone is inadequate.

AB - Objectives: Renal medullary carcinoma (RMC) is a devastating and extremely rare malignancy primarily afflicting young men with sickle cell trait. We present our clinical experience with 9 cases of RMC during a 10-year period and briefly review the published data. Methods: A retrospective chart review of 9 cases of RMC during a 10-year period at our institutions was performed. The clinical patient characteristics, presentations, treatments, and outcomes were recorded. The radiographic images and pathologic specimens were reviewed. Applicable studies were selected from a Medline search. Results: All 9 patients had sickle cell trait, the male/female ratio was 6:3, and the age range was 13 to 31 years. All the patients presented with flank pain, two thirds had hematuria, and 3 of the 9 patients presented with a palpable mass. Eight of the nine tumors were right sided, ranging from 4 to 12 cm in the greatest diameter. Of the 9 patients, 7 underwent radical nephrectomy. One patient was deemed to have unresectable disease by the operating surgeon, and one was given initial chemotherapy after biopsy of a metastatic lesion. The neoadjuvant therapies varied. Overall survival ranged from 4 to 16 months, with 2 patients still living at the last follow-up visit. Conclusions: Our urban setting likely explains our relatively large experience with this rare and extremely aggressive tumor. An early diagnosis is critical, and a high index of suspicion should be given to any individual with sickle cell trait and new-onset hematuria, especially in the setting of a right-sided mass. Prospective trials are needed for chemotherapy/immunotherapy, because surgical intervention alone is inadequate.

UR - http://www.scopus.com/inward/record.url?scp=36549034353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549034353&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2007.06.1124

DO - 10.1016/j.urology.2007.06.1124

M3 - Article

C2 - 18068443

AN - SCOPUS:36549034353

VL - 70

SP - 878

EP - 882

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -